Navigation Links
Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting

M.D. Anderson, Cleveland Clinic Among Group of Leading Cancer Centers

Presenting Cryoablation Data

IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that cryoablation, a minimally invasive method of freezing cancerous tumors to destroy them, was the focus of 17 clinical studies presented at the six-day annual meeting of the American Urological Association (AUA) in Orlando, which is the largest urology meeting of the year.

Also, a total of six post-graduate educational courses and workshops related to cryoablation were sponsored by the AUA and, for the first time, the AUA adopted a specific set of prostate cancer clinical guidelines for cryoablation. A panel, led by Richard J. Babaian M.D. professor and senior medical director at M.D. Anderson Physician Network, announced a set of best practice statements for primary cryoablation, salvage cryoablation and focal cryoablation.

"The positive outcomes cryoablation has had for thousands of patients were evident in a variety of clinical studies presented by leading physicians and researchers throughout this year's AUA annual meeting," said Endocare Chairman, CEO and President Craig T. Davenport. "The breadth of attention that the AUA now pays to cryoablation, including educational courses, workshops and the adoption of AUA-sponsored clinical guidelines, underscores the acceptance of cryoablation as a safe and effective, minimally invasive treatment for prostate cancer and kidney cancer."

Highlights from the 17 studies include:

-- A wide-ranging review of the outcomes of cryoablation in 2,558 primary

prostate cancer patients showed efficacy of cryoablation in terms of

biochemical survival and low morbidity. The average age of the

patients, all part of the nationwide Cryo-On-Line Database (COLD)

Registry, was 70 years and 419 of the patients had more than five years

of follow-up.

-- A 10-year, retrospective review of 78 patients at the University of

Texas M.D. Anderson Cancer Center demonstrated the effectiveness of

cryoablation for prostate cancer patients whose cancer returned after

being originally treated with radiation. After 10 years, more than 80

percent of the patients were disease free after cryoablation and the

investigators concluded that salvage cryoablation is curative in

approximately one-third of patients at 10-year follow up.

-- The first, multi-center study of focal, or partial gland, cryoablation

for 341 prostate cancer patients demonstrated that more than half of

the patients who were potent before the therapy were again potent after

six months, and more than 74 percent resumed potency within 36 months.

Focal cryoablation is designed to destroy the tumors in the prostate

while sparing the nerves to retain potency. These patients are also

part of the COLD Registry.

-- An 88-patient Cleveland Clinic study of the long term disease-free

survival rates (more than five years) of kidney cancer patients showed

that laparoscopic kidney cryoablation is an effective treatment in

select patients. The investigators determined that cancer-specific

survival of 95 percent is possible at five years and 88 percent is

possible at 10 years.

-- Six AUA-sponsored courses and workshops related to cryoablation

focused on prostate ultrasound, abdominal ultrasound, laparoscopic

techniques, renal ablation, needle ablation of the kidney and

cryoablation of the prostate.

About Endocare

Endocare, Inc. -- -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty regarding the effects of the studies described in this press release and any future follow up data. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact:

Matt Clawson

Allen & Caron, Inc.

(949) 474-4300

Media Contact:

Len Hall

Allen & Caron, Inc.

(949) 474-4300

For Additional Information:

Craig T. Davenport, CEO

Michael R. Rodriguez, CFO

Endocare, Inc.

(949) 450-5400

SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
2. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
3. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
4. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
5. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
6. Tapestry Announces Strategy to Focus on TPI 287 Clinical Program
7. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
8. Rapid Growth of Asia-Pacific Clinical Trials Market Focus of New CenterWatch Report
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
11. Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... 26, 2015 ... "2016 Future Horizons and Growth Strategies ... Market: Supplier Shares, Country Segment Forecasts, Competitive ... offering. --> ) has ... Future Horizons and Growth Strategies in the ...
(Date:11/26/2015)... 2015 ) has ... of High Viscosity Drugs" report to their ... the addition of the "Self Administration of ... --> Research and Markets ( ... "Self Administration of High Viscosity Drugs" report ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... A simply groundbreaking television series, "Voices in America", which is hosted ... array of issues that are presently affecting Americans. Dedicated to providing the world with ... changing the subjects consumers focus on, one episode at a time. , In ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel ... self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with ... work with any font, giving users limitless opportunities to stylize and create designs ...
Breaking Medicine News(10 mins):